Surgical Oncology-Oxford最新文献

{"title":"Corrigendum to \"The expression of stem cell protein Piwil2 and piR-932 in breast cancer\" [Surg. Oncol. (2013) 22(4) 217-23].","authors":"Hao Zhang, Yuan Ren, Huanming Xu, Deyan Pang, Chao Duan, Caigang Liu","doi":"10.1016/j.suronc.2025.102214","DOIUrl":"https://doi.org/10.1016/j.suronc.2025.102214","url":null,"abstract":"","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":" ","pages":"102214"},"PeriodicalIF":2.3,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extended pelvic lymphadenectomy and rectal cancer: An umbrella review","authors":"Valentina Villanova ,&nbsp;Alessandro Martinino ,&nbsp;Emilia Stanzani ,&nbsp;Paola Pastena ,&nbsp;Laura Lorenzon ,&nbsp;Francesco Giovinazzo ,&nbsp;on behalf of the SMAGEICS Group","doi":"10.1016/j.suronc.2025.102215","DOIUrl":"10.1016/j.suronc.2025.102215","url":null,"abstract":"<div><div>Extended pelvic lymph node dissection (EPLND) for rectal cancer is common in Asian countries to reduce local recurrence and improve survival. This umbrella review investigates the benefit of adding extended lymphadenectomy to the standard total mesorectal excision (TME) practice. We conducted a comprehensive search of PubMed, Scopus, and Web of Science to identify systematic reviews and meta-analyses examining the role of EPLND in rectal cancer surgery. Primary outcomes were local recurrence and overall survival; secondary outcomes included: operation time, blood loss, urinary dysfunction, and sexual dysfunction. Of the 953 articles screened, 12 met the inclusion criteria. The median follow-up time was 52 months. In terms of overall survival, 10 studies found no statistically significant difference in the EPLND group; only two showed a significant improvement in 5-year survival. Nine studies found no significant benefit of EPLND in preventing local recurrence, while two suggested benefits for patients with locally advanced cancer after neoadjuvant chemoradiotherapy. In most studies, operation time and blood loss were higher in the EPLND group. EPLND was associated with increased odds of urinary and sexual dysfunction, with four out of six studies reporting higher rates for both outcomes. Our analysis concludes that EPLND offers no additional benefit over TME alone in terms of local recurrence, overall survival, or secondary outcomes, including increased risks of urinary and sexual dysfunction, longer operation times, and greater blood loss.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"60 ","pages":"Article 102215"},"PeriodicalIF":2.3,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LogODDS as a prognostic factor in oral cavity squamous cell carcinoma","authors":"Giada A. Beltramini ,&nbsp;Edoardo F. Montrasio ,&nbsp;Filippo Da Pozzo ,&nbsp;Alessandro Cherchi ,&nbsp;Domenico Sfondrini ,&nbsp;Andrea Sacconi","doi":"10.1016/j.suronc.2025.102213","DOIUrl":"10.1016/j.suronc.2025.102213","url":null,"abstract":"<div><div>The objective of the study is to estimate the role of LogODDS as a prognostic factor in patients affected by oral cavity squamous cell carcinoma, in terms of overall survival (OS) and disease-free survival (DFS), looking for a cut-off value that allows to stratify them in high and low risk of recurrency, implementing the informations given by Lymph Node Ratio (LNR) and TNM 8th.</div><div>Seventyfour patients affected by oral cavity squamous cell carcinoma with metastatic lymph nodes who have undergone surgery at Maxillofacial Surgery Unit of the Fondazione IRCCS Cà Granda Ospedale Policlinico di Milano, in which a restaging according to TNM 8th was possible and LNR and LogODDS could have been calculated, were enrolled.</div><div>Multivariate analysis for OS was statistically relevant for both LogODDS and LNR, where N alone didn't reach the same result. No one of the previous parameters has a statistically relevant meaning in DFS prediction.</div><div>LogODDS as a prognostic factor has a statistically compelling meaning in order to predict overall survival in oral squamous cell carcinoma.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"60 ","pages":"Article 102213"},"PeriodicalIF":2.3,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of hepatectomy for HCC with PVTT: Insights from a 30-year single-center experience","authors":"Zhicheng Yao ,&nbsp;Yupeng Ren ,&nbsp;Mingbo Cao ,&nbsp;Yuxuan Li ,&nbsp;Xiaorui Su ,&nbsp;Ziyi Hu ,&nbsp;Pei Han ,&nbsp;Ho Kam Yuen ,&nbsp;Tan To Cheung","doi":"10.1016/j.suronc.2025.102211","DOIUrl":"10.1016/j.suronc.2025.102211","url":null,"abstract":"<div><h3>Background and aim</h3><div>Portal vein tumor thrombosis (PVTT) is frequent in hepatocellular carcinoma (HCC). Although hepatectomy is the primary treatment for HCC, no consensus exists on its role in PVTT between Eastern and Western clinicians. This study aims to assess the efficacy of hepatectomy in HCC patients with PVTT by analyzing perioperative outcomes and prognosis.</div></div><div><h3>Methods</h3><div>This retrospective, single-center study reviewed HCC patient data from Queen Mary Hospital, Hong Kong (1989–2020). Propensity score matching (PSM) was applied to match patients with and without PVTT undergoing hepatectomy, comparing perioperative and survival outcomes between groups.</div></div><div><h3>Results</h3><div>Among 3981 HCC patients, 1842 had PVTT and were not operated (not-operated group), while 2139 underwent hepatectomy. Of the operated patients, 156 had PVTT (PVTT group) and 1983 did not (no-PVTT group). Median overall survival (mOS) in the not-operated group was 2.7 months, compared to 13.0 months in the PVTT group. After 1:3 PSM, the no-PVTT group (n = 468) had longer mOS (47.0 vs. 13.0 months, p &lt; 0.001) and disease-free survival (10.6 vs. 4.2 months, p &lt; 0.001). The PVTT group had longer operative times (449 vs. 390 min, p &lt; 0.001), higher complication rates (37.8 % vs. 28.2 %, p = 0.024), and closer surgical margins (0.6 vs. 1.0 cm, p = 0.036), but similar hospital mortality (p = 0.898). mOS for low-AFP (&lt;17400 ng/ml) and high-AFP (≥17400 ng/ml) patients was 16.2 vs. 8.2 months, respectively (p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Aggressive treatment of PVTT is necessary. For certain PVTT patients, hepatectomy may be potentially effective, with acceptable perioperative safety and seemingly no technical barriers.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"60 ","pages":"Article 102211"},"PeriodicalIF":2.3,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143681035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete pathological response to neoadjuvant chemoradiotherapy is associated with improved long-term survival after surgical treatment for rectal cancer","authors":"Elias Khajeh ,&nbsp;Sanam Fakour ,&nbsp;Constanze Zeh-Ressel ,&nbsp;Marzieh Jafari ,&nbsp;Rajan Nikbakhsh ,&nbsp;Ali Ramouz ,&nbsp;Arianeb Mehrabi ,&nbsp;Markus W. Büchler ,&nbsp;Yakup Kulu","doi":"10.1016/j.suronc.2025.102206","DOIUrl":"10.1016/j.suronc.2025.102206","url":null,"abstract":"<div><h3>Background</h3><div>Tumor regression after neoadjuvant chemoradiotherapy can improve the long-term outcomes of rectal cancer. However, it is unclear how the tumor regression grade (TRG) relates to long-term outcomes. We evaluated how the TRG affects overall survival in patients with rectal cancer who underwent neoadjuvant chemoradiotherapy prior to radical surgery.</div></div><div><h3>Methods</h3><div>All patients who underwent low anterior resection for rectal cancer after chemoradiotherapy over a 13-year period were included in this study. Perioperative and histopathological data of patients, including the TRG (categorized as no regression, minimal regression, moderate regression, near complete regression and complete regression) were evaluated. The correlation of TRG with overall survival was assessed using the log-rank test and Cox proportional hazards regression analysis.</div></div><div><h3>Results</h3><div>During the study period,193 patients underwent low anterior rectal resection after neoadjuvant chemoradiotherapy. The 90-day mortality rate was 1.5 % and the median follow up was 69.5 months. The 5-year and 10-year overall survival rates were 85.0 % and 69.8 %, respectively. Patients with complete regression had a significantly higher 10-year overall survival rate than other patients (87.3 % vs. 66.5 %, p = 0.031). Multivariate analysis revealed that older age (hazard ratio [HR] = 2.4,95 % confidence interval [95 % CI] = 1.3–4.6, p = 0.007) and complete pathological response (HR = 0.23, 95 % CI = 0.06–0.96, p = 0.044) were independent predictors of overall survival.</div></div><div><h3>Conclusion</h3><div>Complete pathological response after neoadjuvant therapy for rectal cancer improves overall survival after surgery. Further studies are needed to determine the factors that predict complete TRG to identify patients who would benefit most from neoadjuvant chemoradiotherapy.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"60 ","pages":"Article 102206"},"PeriodicalIF":2.3,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143681036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Life after oncoplastic surgery (IRONY) trial: Preliminary results","authors":"Paolo Orsaria ,&nbsp;Antonella Grasso ,&nbsp;Lorenza Caggiati ,&nbsp;Edy Ippolito ,&nbsp;Francesco Pantano ,&nbsp;Claudia Piccolo ,&nbsp;Vittorio Altomare","doi":"10.1016/j.suronc.2025.102205","DOIUrl":"10.1016/j.suronc.2025.102205","url":null,"abstract":"<div><h3>Background</h3><div>Today partial reconstruction in breast cancer (BC) surgery involves displacement or replacement procedures to improve cosmesis without compromising safety. However, patient satisfaction should be compared among several options, in order to get additional criteria for a personalized approach. The aim is evaluate oncological, aesthetic and functional results after monolateral (reshaping or replacement) or bilateral (mammoplasty with contralateral pexy or reduction) conserving strategies.</div></div><div><h3>Materials and methods</h3><div>The protocol provides for the enrollment of a prospective sample of 250 patients in a time frame of 3 years. The first 108 cases (range 18–85 years) with BC diagnosis, and suitable for type 1–2 oncoplastic surgery who gave informed consent, were selected Data analysis was focused on radicality, complications, cosmetic and functional results related to quality of life, comparing monolateral (ML) and bilateral (BL) groups.</div></div><div><h3>Results</h3><div>Tumor size (p = 0.01), multifocality (p = 0.05), multicentricity (p = 0.01) and estimated resection volume (p = 0.000) were higher in the BL group. There was a comparable re-excision rate for positive margins (p = 0.72), and after 2.3 years, no difference in local recurrences were recorded. No early (p &gt; 0.05), but late complications were more common in the BL (p = 0.07). The overall satisfaction with cosmesis and well-being were characterized by similar proportions of good results (p&gt;0.05), with some details more related to each procedure.</div></div><div><h3>Conclusion</h3><div>The proposed techniques represent effective solutions for reshaping that follows BC excision, achieving comparable early complications, low re-interventions with good aesthetic results and social functioning. However, is crucial a careful patient selection and surgical plan while predicting any sequel or delayed complication during follow-up.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"59 ","pages":"Article 102205"},"PeriodicalIF":2.3,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143619205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in disease presentation among patients with papillary thyroid cancer: A retrospective cohort study","authors":"Nina Rodriguez ,&nbsp;Dragan Vujovic ,&nbsp;Mathilda Alsen ,&nbsp;Eric Genden ,&nbsp;Maaike van Gerwen","doi":"10.1016/j.suronc.2025.102212","DOIUrl":"10.1016/j.suronc.2025.102212","url":null,"abstract":"<div><h3>Purpose</h3><div>Prior research suggests that racial and ethnic minorities present with advanced papillary thyroid cancer (PTC), traditionally defined using surgical pathology. However, marginalized populations are more likely to experience delays in surgical treatment, raising concerns that surgical staging may misrepresent the extent of disease at initial presentation. This study investigates disparities in disease presentation using cytology from Fine Needle Aspiration (FNA), which is performed at first evaluation and precedes surgery, in an institutional cohort of PTC patients.</div></div><div><h3>Methods</h3><div>A single-site retrospective review of 405 patients with PTC from 2018 to 2019 evaluated the association between sociodemographic variables and the likelihood of presenting with cytologically-confirmed malignancy using FNA. Patients with malignant cytology (Bethesda VI) were compared to those with unconfirmed malignancy (Bethesda III-V). To validate the clinical significance of the Bethesda VI classification, we conducted an additional analysis examining whether these patients presented with more advanced disease.</div></div><div><h3>Results</h3><div>Patients classified as Bethesda VI on FNA were younger and more likely to present with advanced disease features, compared to Bethesda III-V patients. On multivariable analysis, patients in the lowest income group were significantly more likely to present with Bethesda VI compared to those in the highest income group.</div></div><div><h3>Conclusion</h3><div>Differences in initial presentation were observed in our institutional cohort of PTC patients. Lower median household income was independently associated with presenting with Bethesda VI, even after adjusting for race/ethnicity. This analysis highlights the clinical relevance of considering factors beyond race and ethnicity alone to better tailor early detection efforts and strategic resource allocation, thereby addressing disparities more effectively.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"59 ","pages":"Article 102212"},"PeriodicalIF":2.3,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic outcome of tumor deposit in colorectal cancer beyond stage N staging","authors":"Tanasit Saikeaw,&nbsp;Phadungkiat Tipmanee,&nbsp;Pasut Chareonpornwattana,&nbsp;Gritcharat Watthanasathitarpha,&nbsp;Kanyanat Dasom,&nbsp;Thitithep Limvorapitak","doi":"10.1016/j.suronc.2025.102203","DOIUrl":"10.1016/j.suronc.2025.102203","url":null,"abstract":"<div><h3>Background</h3><div>Tumor deposits (TD) have been shown to have prognostic implications in patients diagnosed with colorectal cancer (CRC), although their impact appears to be modest compared to regional lymph node metastases.</div></div><div><h3>Patients and methods</h3><div>A retrospective analysis was conducted involving patients with colorectal cancer in stages I-III who underwent curative resections between January 2015 and December 2019 in the tertiary care center in Thailand. These patients were divided into two cohorts: TD positive and TD negative. Additionally, the patients were subsequently classified into N0, N1, and N2 groups. Disease-free survival and overall survival were compared.</div></div><div><h3>Results</h3><div>Among the 1015 eligible patients, 176 (17.3 %) had tumor deposits (TD), while 374 patients (36.8 %) had positive lymph nodes (LN). The TD positive group demonstrated a significantly lower 5-year overall survival rate (OS) and 5-year disease-free survival rate (DFS) compared to the TD negative group (73.5 % vs 85.9 %, p &lt; 0.001 and 72.5 % vs 87.9 %, p &lt; 0.001 respectively). Upon stratification by various N stages, the presence of TD was notably associated with DFS in the N1 group (5-year DFS: 84.3 % vs. 89.2 %, p = 0.006). Multivariate logistic analyses shown TD as an independent predictor of disease recurrence [p = 0.02; hazard ratio (HR):1.71 (1.11–2.64)].</div></div><div><h3>Conclusion</h3><div>The presence of TD was significantly correlated with reduced overall survival (OS) and disease-free survival (DFS) in colorectal cancer, especially in patients with nodal metastases.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"59 ","pages":"Article 102203"},"PeriodicalIF":2.3,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preserving potential: Surgeons as key partners in establishing a living sarcoma biobank for translational research purposes","authors":"Stefanie Gijsels ,&nbsp;Merlijn Vekeman ,&nbsp;Suzanne Fischer ,&nbsp;David Creytens ,&nbsp;Alexander Ackerman ,&nbsp;Anais Ongenaet ,&nbsp;Laurens Boi ,&nbsp;Eline Segers ,&nbsp;Jens De Temmerman ,&nbsp;Francesca Casteur ,&nbsp;Ruben Van Boxstael ,&nbsp;Herlinde De Waele ,&nbsp;Desirée Dorleijn ,&nbsp;Fleur Cordier ,&nbsp;Lore Lapeire ,&nbsp;Gabriëlle Van Ramshorst ,&nbsp;Olivier De Wever ,&nbsp;Gwen Sys","doi":"10.1016/j.suronc.2025.102209","DOIUrl":"10.1016/j.suronc.2025.102209","url":null,"abstract":"<div><h3>Background</h3><div>Sarcoma is a rare type of cancer, of which over 70 distinct molecular subtypes are known. Because these tumours are so rare and complex, treatment outcomes have remained similar over the past decades and research is progressing slowly. For these rare cancers, personalised medicine and patient-derived models might pose solutions for therapeutic problems, but researchers depend on clinicians to access fresh, viable tumour tissue.</div></div><div><h3>Methods</h3><div>Over the past five years, a bedside-to-bench flow was implemented in Ghent University Hospital for a living biobank of sarcoma tissue to support translational research. All tumour tissue was cryopreserved in cryopreservation medium (90 % foetal bovine serum and 10 % dimethyl sulfoxide) maintaining viability of the tissue.</div></div><div><h3>Results</h3><div>As of July 2024, this biobank houses 217 sarcoma samples available for model development, biomarker discovery and precision medicine initiatives. The samples were collected from 167 patients, with 40 patients of whom we collected several samples throughout the disease course.</div></div><div><h3>Discussion</h3><div>With this article, we aim to incentivise surgeons to engage in biobanking initiatives, as they have a unique position with direct access to fresh tumour tissue. We present our biobank and clinical flow that is implemented in daily clinical practice. The primary aim of the biobank is to advance sarcoma research by creating models and sharing data with fellow researchers.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"59 ","pages":"Article 102209"},"PeriodicalIF":2.3,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143579061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synovial sarcoma: The influence of clinicopathological variables on overall survival in a UK population","authors":"Bill Robertson-Smith ,&nbsp;Jackie Campbell ,&nbsp;Karen Anthony ,&nbsp;Thomas A. McCulloch ,&nbsp;Robert U. Ashford","doi":"10.1016/j.suronc.2025.102204","DOIUrl":"10.1016/j.suronc.2025.102204","url":null,"abstract":"<div><h3>Introduction</h3><div>Synovial sarcoma accounts for 5%–10 % of malignant soft-tissue tumours. Curative treatment includes surgery, with radiotherapy and/or chemotherapy. With no specific treatment regimen for synovial sarcoma, the primary aim of this research was to describe the characteristics of a regional synovial sarcoma population in the UK, and to investigate clinicopathological variables associated with overall survival.</div></div><div><h3>Methods</h3><div>Ninety-four patients with synovial sarcoma from the East Midlands Sarcoma Service database were pseudo anonymised and clinicopathological variables extracted. Kaplan-Meier and Cox regression statistical analyses were used to identify variables affecting overall survival.</div></div><div><h3>Results</h3><div>Mean age at diagnosis was 42 years (range 8–83 years). Over half (n = 50, 53 %) of patients had a tumour in the lower limb. Thirty-seven (39.6 %) had a tumour size of &lt;5 cm. Sixteen (17 %) patients had local recurrence, and under half (n = 40, 43.5 %) developed metastatic disease. Most patients (n = 63, 63 %) were initially treated with surgery. The majority (n = 58, 61.7 %) had a monophasic subtype, and the overall survival of the whole cohort was 83 months (95 % CI 39.1–127.8). Increasing tumour size and distant recurrence (metastasis) had a significantly negative impact on median overall survival (<em>p</em> = 0.0001). Patients who underwent surgery and radiotherapy had a significantly better median overall survival (<em>p</em> = 0.02). Multivariable analysis identified adjuvant radiotherapy (<em>p</em> = 0.039), lower limb tumour (<em>p</em> = 0.033), and tumour size (&lt;5 cm <em>p</em> = 0.006, 5–10 cm <em>p</em> = 0.0001, &gt;10 cm <em>p</em> = 0.013) as significant survival predictors.</div></div><div><h3>Conclusion</h3><div>Adjuvant radiotherapy is a novel independent prognostic marker for synovial sarcoma.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"59 ","pages":"Article 102204"},"PeriodicalIF":2.3,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143654469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}